Lexaria Bioscience (LEXX) Expected to Release Earnings on Wednesday

Lexaria Bioscience (NASDAQ:LEXX) is anticipated to post its Q4 2026 results before the market opens on Wednesday, October 28th. Analysts expect Lexaria Bioscience to post earnings of ($0.90) per share and revenue of $0.05 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 12:00 AM ET.

Lexaria Bioscience Stock Performance

Shares of LEXX opened at $2.92 on Tuesday. Lexaria Bioscience has a 52 week low of $2.43 and a 52 week high of $21.60. The firm has a market cap of $6.16 million, a P/E ratio of -0.57 and a beta of 0.61. The firm’s 50-day simple moving average is $5.89 and its 200 day simple moving average is $9.12.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings downgraded shares of Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Wall Street Zen upgraded Lexaria Bioscience to a “sell” rating in a report on Saturday, October 10th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.50.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.

The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients.